Pharmaceutical

Coeptis licenses Deverra Therapeutics’ clinical stage assets

Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.

Aug 18, 2023 - 20:00
Coeptis licenses Deverra Therapeutics’ clinical stage assets
Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.
Read the original article

Tags:

Previous Article

Signal: Abortion pill restriction may drive more patients to off-label drug

Next Article

Bruker to buy cell biology company PhenomeX for $108m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Pierre Fabre announces another partnership to expand oncology R&D

Pierre Fabre announces another partnership to expand on...

Sep 25, 2023

The Witty Answer to GSK’s Future

The Witty Answer to GSK’s Future

Apr 16, 2023

STAT+: Acelyrin, a rare IPO success, stumbles in its first big test

STAT+: Acelyrin, a rare IPO success, stumbles in its fi...

Sep 12, 2023